CLINICAL_TRIALS
trial_result
· 2021-06-09
Clinical Trial Update: Pembrolizumab in First Line Treatment of Advanced NSCLC Patients With PD-L1 Low Tumors. [Phase 2]
Summary
Phase 2 trial update on pembrolizumab as first-line treatment for advanced NSCLC with low PD-L1 expression.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Conditions: Non Small Cell Lung Cancer (NSCLC) | Phase 2 | Status: UNKNOWN